ReproCELL: Notice regarding differences between full-year individual results for the fiscal year ending March 31, 2024 and results for the previous fiscal year
ReproCELL: Notice regarding subsidies to consolidated subsidiaries (REPROCELL USA Inc.)
ReproCELL: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
ReproCELL: Notice regarding the recording of non-operating income, extraordinary loss, and revisions to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2024
ReproCELL: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
ReproCELL: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
ReproCELL: Partial correction to “Notice of patent registration in Japan relating to treatment of polyglutamine disease by Steminent”
ReproCELL: Notice of patent registration in Japan relating to treatment of polyglutamine disease by Steminent
ReproCELL: Notice Concerning Permission to Exercise the 16th Stock Acquisition Rights (with Exercise Price Amendment Clauses and Exercise Permission Clauses) through Third-Party Allotment
ReproCELL: Notice regarding adoption of the AMED public offering project “Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy”
Reprocel: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
Reprocel: Notice regarding listing of the investor Stemminent on the Taiwan Emerging Stock Board
Reprocess: Change Report (Stock Certificates Subject to Special Cases, etc.)
Reprocel: Notice regarding the monthly exercise status of the 16th Stock Acquisition Rights (with exercise price amendment clauses and exercise permission clauses)
ReproCELL: Notice Concerning Mass Exercise of the 16th Stock Acquisition Rights (with Exercise Price Amendment Clauses and Exercise Permit Clauses)
Reprocess: Confirmation
Reprocel: Quarterly Report - 22nd Quarter 3rd Quarter (2023/10/01 to 2023/12/31)
ReproCELL: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
ReproCELL: Notice regarding a decrease in non-operating income (foreign exchange profit)
ReproCELL: Notice of new pipeline decision for tumor-infiltrating lymphocyte infusion therapy (TIL therapy)
No Data